Immune checkpoint blockade targets macrophage PD-1 to exacerbate metabolic dysfunction-Immunometabolism-CSCIED科技核心评价数据库-手机版

Immune checkpoint blockade targets macrophage PD-1 to exacerbate metabolic dysfunction

Immune checkpoint blockade targets macrophage PD-1 to exacerbate metabolic dysfunction

ES评分 0 浏览量：357 下载量：0

DOI	10.1097/IN9.0000000000000079
刊名	Immunometabolism IJ
年，卷(期)	2026, 8(2)
作者	Song, Zikuan; Frezza, Christian,
作者单位	Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany
摘要	Immune checkpoint inhibitor therapies induce metabolic dysfunction. A study by Wu et al now pinpoints macrophage programmed cell death protein 1 (PD-1) as a key molecular mediator of the anti-PD-1 treatment-triggered exacerbation of systemic metabolic disorders. Macrophage PD-1 blockade disrupts the moonlighting function of PD-1 in suppressing endoplasmic reticulum stress-mediated inflammatory responses, thereby impairing adipose tissue thermogenesis, reducing energy expenditure, and ultimately leading to systemic metabolic dysfunction.
Abstract	Immune checkpoint inhibitor therapies induce metabolic dysfunction. A study by Wu et al now pinpoints macrophage programmed cell death protein 1 (PD-1) as a key molecular mediator of the anti-PD-1 treatment-triggered exacerbation of systemic metabolic disorders. Macrophage PD-1 blockade disrupts the moonlighting function of PD-1 in suppressing endoplasmic reticulum stress-mediated inflammatory responses, thereby impairing adipose tissue thermogenesis, reducing energy expenditure, and ultimately leading to systemic metabolic dysfunction.
基金项目
页码	-

参考文献
相关文献

[1]. Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652-69.

[2]. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223-49.

[3]. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384-91.

[4]. Javed SA, Najmi A, Ahsan W, et al. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Front Immunol. 2024;15:1383456.

[5]. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.

[6]. Jayathilaka B, Mian F, Franchini F, et al. Correction: cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer. 2025;132(1):137.

[7]. Zhou L, Yang S, Li Y, et al. A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis. Front Immunol. 2024;15:1448728.

[8]. Wu MM, Yang YC, Hu ZQ, et al. Macrophage PD-1 regulates energy expenditure and metabolic dysfunction under immune checkpoint blockade. Cell Metab. 2026;38(1):208-27.e12.

[9]. Wu L, Tsang V, Clifton-Bligh R, et al. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations. J ImmunoTher Cancer. 2025;13(6):e011271.

[10]. Bader JE, Wolf MM, Lupica-Tondo GL, et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature. 2024;630(8018):968-75.

[11]. Imbert C, Montfort A, Fraisse M, et al. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nat Commun. 2020;11(1):437.

[12]. Lyu A, Fan Z, Clark M, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637(8048):1207-17.

[13]. Dubrot J, Lane-Reticker SK, Kessler EA, et al. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity. 2021;54(3):571-85.e6.

[14]. Sehgal K, Costa DB, Rangachari D. Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic? Front Oncol. 2020;10:1193.

[15]. Jiang M, Hu Y, Lin G, et al. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol. 2022;12:906251.

[16]. Rajagopal D, MacLeod E, Corogeanu D, et al. Immune-related adverse events of antibody-based biological medicines in cancer therapy. J Cell Mol Med. 2024;28(13):e18470.

[17]. Lengyel E, Makowski L, DiGiovanni J, et al. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer. 2018;4(5):374-84.

[18]. Garner H, de Visser KE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol. 2020;20(8):483-97.

[19]. Lin MH, Ye RH, Jhou HJ, et al. Immune checkpoint inhibitor therapy and risk of type 1 diabetes mellitus in metastatic cancer patients. Diabetol Metab Syndr. 2025;17(1):377.

[20]. Liu Y, Zugazagoitia J, Ahmed FS, et al. Immune Cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26(4):970-7.

[21]. Zhou XMM, Williams K, Will E, et al. PD-L1-negative macrophages are associated with poor outcomes and high-grade immune-related adverse event development in patients with melanoma receiving anti-PD-1 immunotherapy. J Invest Dermatol. 2026;146(4):1143-6.

引用本文

Song, Zikuan; Frezza, Christian. Immune checkpoint blockade targets macrophage PD-1 to exacerbate metabolic dysfunction [J]. Immunometabolism. 2026; 8; (2). - .

文献评论

相关学者

相关机构